Investing in Concert Pharmaceuticals, Inc. (CNCE)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)2.95Infinity
Intrinsic value (DCF)2.95Infinity
Graham-Dodd Method0.00NaN
Graham Formula89.21Infinity

Company description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.